In ‘Real Life’ this 10-day Ivermectin Triple Therapy reported here, appears to be a very safe, effective and inexpensive early antiviral treatment for Covid-19. Further detail from the more than 30 doctors involved in treating this patient group, will be used for a formal peer-reviewed publication.
It is irresponsible to exclude IVM as a drug to control high numbers of infections that will be encountered as Australia moves out of its “bubble”, irrespective of the level of vaccination.
In the second part of our interview with the esteemed Professor Thomas Borody from Australia, we discuss the question of ethical clinical trials, the progress in Australia with the Ivermectin-based tri-therapy he recommends for COVID-19, the role of State and federal authories.
We treat them for 10 days using an appropriate dose of ivermectin, doxycycline daily and zinc daily.
They all actually have activity against the intracellular multiplication of the virus and from published data you can read that most of the results have been close to 100 percent cure there was one that used the lower level and got 92 percent cure but it’s just hard to believe how simple it is to cure coronavirus.
Borody’s ivermectin triple therapy prophylactic is the perfect solution. It reduces transmission immediately, regardless of the variant, by preventing the virus from entering a person’s cells. It also shortens time spent in quarantine and reduces transmission to close contacts. Early treatment dramatically reduces hospitalisation and mortality and would rapidly end the Sydney wave, as similar therapies did in Mexico and India. It would also put an end to any need for masks and lockdowns.
At this point, continuing the use of Ivermectin has proven safe and we see no reason to stop this drug, which seems to have not only inhibited our second wave but so far prevented a third one.
aken together, Ivermectin– a treatment for head lice that costs as little as $2 – combined with zinc and the antibiotic
Doxycycline, could be a “potential lifesaver right now”, Professor Borody said. “These three medications are already approved,” he said.
“They do not need preclinical or clinical trials nor additional (Therapeutic Goods Administration) approvals unless the aim is to combine in a single capsule, for example.
Patient treatment programs have been done in the US and elsewhere which indicate it can work within four to six days.”
